RBD4059 is listed as a product in 2 authorised or ongoing trials in the EU clinical trials register (CTIS). All registered phases are Phase 2. The sponsor is Ribocure Pharmaceuticals AB. It does not appear under this name in the ClinicalTrials.gov records behind our other registers.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product named RBD4059. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Randomized, Double blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants with Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)
2026-525479-15-00 · Cardiovascular Diseases
|
Phase 2 | Authorised | Ribocure Pharmaceuticals AB | Poland, Romania, France + 1 more |
|
A randomised active-controlled trial to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation
2026-525417-31-00 · Cardiovascular Diseases
|
Phase 2 | Authorised | Ribocure Pharmaceuticals AB | Norway, Denmark, Poland + 1 more |
| Lead sponsor | Trials |
|---|---|
| Ribocure Pharmaceuticals AB | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| EU register (CTIS) | 2 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 authorised or ongoing trials in the EU clinical trials register (CTIS) list a product named RBD4059, as of the registry sync on 26 September 2026. It is not named in the ClinicalTrials.gov records behind our Ireland, UK, USA, India and China registers.
The lead sponsor is Ribocure Pharmaceuticals AB. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public EU CTIS records by a daily sync. Nothing here describes how RBD4059 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RBD4059 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RBD4059 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.